文献速递肾小球疾病

硼替佐米靶向浆细胞治疗难治性IgA肾病的前瞻性初步研究

Prospective Pilot Study of Plasma Cell-Targeted Therapy With Bortezomib in Refractory IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2025-06-11

这项开放标签、前瞻性、非对照试验评估硼替佐米治疗活检确诊、蛋白尿>1.5 g/d且eGFR≥30 ml/min/1.73 m²的成人IgA肾病患者,16例完成研究。12个月时蛋白尿降低44.67%,6.25%达完全缓解,43.75%达≥50%降低;24个月蛋白尿降低48.09%,年eGFR斜率为-4.275 ml/min/1.73 m²,未报告严重治疗相关不良事件。

要点

  • 硼替佐米短程治疗使IgA肾病患者蛋白尿持续降低,12个月降低44.67%。
  • 16例中6.25%达完全缓解,43.75%达蛋白尿≥50%降低。
  • 年eGFR斜率为-4.275 ml/min/1.73 m²,未报告严重治疗相关不良事件。

核心结论

  • 短程硼替佐米治疗使IgA肾病患者蛋白尿持续降低,安全性可接受,结果支持在更大规模对照试验中进一步评估。

研究设计与样本

  • 开放标签、前瞻性、非对照试验,纳入活检确诊IgA肾病、蛋白尿>1.5 g/d且eGFR≥30 ml/min/1.73 m²的成人患者,16例完成研究。
  • 患者接受4至8剂静脉硼替佐米,每剂1.1至1.3 mg/m²。
  • 主要终点为12个月时24小时蛋白尿<300 mg/24 h。

主要发现

  • 基线蛋白尿为2.719 g/24 h(95%CI:2.169-3.408),平均eGFR为51.1 ml/min/1.73 m²(95%CI:41.3-60.8)。
  • 12个月时蛋白尿降低44.67%,6.25%达完全缓解,43.75%达≥50%降低。
  • 24个月时蛋白尿降低持续,平均1.411 g/24 h,降低48.09%。
  • 年eGFR斜率为-4.275 ml/min/1.73 m²。
  • 未报告严重治疗相关不良事件。

局限性

  • 原文未报告局限性。
  • 原文结论指出结果支持在更大规模对照试验中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IgA nephropathy (IgAN) is a leading cause of kidney failure, characterized by galactose-deficient IgA1 (Gd-IgA1) deposition and immune complex formation. Aberrant trafficking of IgA+ plasma cells and autoantibody production (IgG or IgA) contribute to disease pathogenesis. Proteasome inhibitors such as bortezomib may modulate B or plasma cell activity and reduce pathogenic antibody production. METHODS: This open-label, prospective, uncontrolled trial evaluated bortezomib in adults with biopsy-confirmed IgAN, proteinuria > 1.5 g/d, and estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2 despite optimized care. Patients received 4 to 8 doses of i.v. bortezomib at 1.1 to 1.3 mg/m2 per dose. The primary end point was achieving 24-hour proteinuria (24 h-UP) < 300 mg/24 h at 12 months. Secondary end points included changes in eGFR and adverse event monitoring. RESULTS: Sixteen patients completed the study. Median time from diagnosis to treatment was 63 months (range: 10-192). Baseline proteinuria was 2.719 g/24 h (95% confidence interval [CI]: 2.169-3.408), and mean eGFR was 51.1 ml/min per 1.73 m2 (95% CI: 41.3-60.8). At 12 months, proteinuria decreased by 44.67%, with 6.25% achieving complete remission and 43.75% achieving ≥ 50% reduction. Proteinuria reduction persisted at 24 months (mean: 1.411 g/24 h: 48.09% reduction). The annual eGFR slope was -4.275 ml/min per 1.73 m2. No serious treatment-related adverse events were reported. CONCLUSION: Short course bortezomib therapy led to sustained proteinuria reduction in patients with IgAN, with an acceptable safety profile. These results support further evaluation in larger, controlled trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lin L, Ren H, Li X, et al. Prospective Pilot Study of Plasma Cell-Targeted Therapy With Bortezomib in Refractory IgA Nephropathy. Kidney Int Rep. 2025. PMID: 40980670. doi:10.1016/j.ekir.2025.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。